Approximately two-thirds of patients admitted to the intensive care unit (ICU) for coronavirus disease-19 (COVID-19) pneumonia present with the acute respiratory distress syndrome (ARDS) \[[@CR1]\]. COVID-19-associated acute cardiac injury is frequently reported based on troponin and electrocardiographic changes \[[@CR2]\], but its impact on cardiac function is yet unknown \[[@CR3]\]. Accordingly, we sought to describe cardiovascular phenotypes identified using transesophageal echocardiography (TEE) in ventilated COVID-19 patients with ARDS and to compare them to those of patients with flu-induced ARDS.

All patients with confirmed COVID-19 who were mechanically ventilated for ARDS in our medical-surgical ICU underwent prospectively a TEE assessment during the first 3 days and whenever required by clinical events during ICU stay, as a standard of care. Similarly, all patients ventilated for flu-associated ARDS who underwent a TEE assessment over the last 2 years were retrospectively analyzed for comparison. Cardiovascular phenotypes were identified using previously reported TEE criteria \[[@CR4]\]. Same applied for acute cor pulmonale (ACP) \[[@CR5]\]. TEE studies were read by two independent experts who had no access to the cause of ARDS and examination date. Results are expressed as medians and 25th--75th percentiles. Friedman ANOVA was used to compare quantitative parameters over time in COVID-19 patients, while Mann-Whitney *U* test and Fisher's exact test were used for comparison of continuous and categorical variables, respectively, with flu patients. No use of previous value or interpolation rule was used in the presence of missing data.

Eighteen consecutive COVID-19 patients and 23 flu patients (21 A-H1N1) were studied. COVID-19 patients were significantly older (70 \[57--75\] vs. 58 \[49--64\] years, *p* = 0.006), less severe (SAPSII 34 \[30--38\] vs. 43 \[32--54\], *p* = 0.015; SOFA 4 \[2--4\] vs. 6 \[4--9\], *p* \< 0.001), required less vasopressor support (2/18 \[11%\] vs. 10/23 \[43%\], *p* = 0.038), and had longer time lag between first symptoms and ICU admission, tracheal intubation, and TEE examination when compared to flu patients (Table [1](#Tab1){ref-type="table"}). The prevalence of left ventricular (LV) failure (3/18 \[17%\] vs. 14/23 \[61%\], *p* = 0.009), ACP (3/18 \[17%\] vs. 11/23 \[48%\], *p* = 0.051), and severe ACP (1/18 \[5.5%\] vs. 8/23 \[35%\], *p* = 0.054) was significantly lower in COVID-19 patients. Hypovolemic and hyperkinetic phenotypes were similarly observed in both groups (Table [1](#Tab1){ref-type="table"}). Despite similar tidal volume and PEEP level, COVID-19 patients had significantly higher P/F ratio and respiratory-system compliance, and lower driving pressure than flu patients (Table [1](#Tab1){ref-type="table"}). Pulmonary embolism was identified in none of COVID-19 patients but in one flu patient with ACP. COVID-19 patients with ACP tended to exhibit lower respiratory-system compliance (34, 32, and 30 mL/cmH~2~O) when compared to others (40 \[31--45\] mL/cmH~2~O). Hemodynamic profile of COVID-19 patients remained stable during the first 3 days of ICU stay (Table [2](#Tab2){ref-type="table"}). Table 1Characteristics, presentation and outcome of ventilated patients with COVID-19 and flu-related ARDSCOVID-19 (*n* = 18)Flu (*n* = 23)*p* valuePatients' characteristics Age, years70 (57--75)58 (49--64)0.006 Male (%)12 (67)12 (52)0.524 BMI, kg/m^2^29 (26--32)29 (25--34)0.519 Hypertension (%)11 (61)10 (43)0.350 Diabetes mellitus (%)4 (22)3 (13)0.679 Time from illness onset to ICU admission, days11 (7--13)5 (4--10)0.017 Time from illness onset to intubation, days12 (8--15)6 (4--10)0.002 Time from illness onset to echocardiography, days14 (9--17)13 (6--17)0.001 SAPS II34 (30--38)43 (32--54)0.015 SOFA score4 (2--4)6 (4--9)\< 0.001Clinical presentation and treatment ECG changes\* (%)1 (5%)3 (13%)0.618 Documented coinfection (%)3 (17)9 (39)0.171 Septic shock (%)0 (%)10 (43)-- Vasopressor support (%)2 (11)10 (43)0.038 Prone position (%)10 (56)14 (61)1.000 Neuromuscular blockers (%)17 (94%)12 (52%)0.005Biology on admission Troponin I (ng/L)73 (51--94)53 (37--66)0.020 Lactate, mmol/L1.17 (0.89--1.57)1.51 (1.02--2.54)0.143 Creatinine, μmol/L58 (42--87)88 (59--160)0.021 Prothombine time, %87 (78--96)87 (71--101)0.979 AST, U/L55 (27--71)107 (46--203)0.020 ALT, U/L37 (27--65)45 (27--115)0.527 CPK, U/L72 (34--103)419 (180--2456)\< 0.001 White blood cell count, G/L7.98 (6.61--11.25)5.96 (4.02--8.05)0.003 Lymphocyte count, G/L0,78 (0.55--1.05)0.75 (0.47--1.13)0.770 Eosinophils count, G/L0.02 (0.02--0.09)0.01 (0.00--0.01)0.094 Platelet count, G/L318 (218--425)172 (153--225)\< 0.001 Hemoglobin, g/dl11.2 (10.2--12.3)13.1 (11.6--14.2)0.007Respiratory parameters PaO~2~/FiO~2~130 (81--217)70 (62--100)\< 0.001 Arterial pH7.35 (7.29--7.45)7.32 (7.23--7.41)0.121 PaCO~2~, mmHg44 (33--51)47 (36--60)0.430 RR, breaths/min24 (22--27)25 (24--28)0.139 Tidal volume, mL/kg5.2 (4.5--6.2)5.3 (4.0--6.1)0.885 PEEP, cmH~2~O10 (8--12)10 (8--12)0.476 Plateau pressure, cmH~2~O23 (20--26)28 (20--28)0.144 Driving pressure, cmH~2~O12 (10--15)18 (17--18)0.001 Respiratory-system compliance\*\*, mL/cmH~2~O38 (31--45)23 (22--27)0.001Hemodynamic parameters Heart rate, bpm90 (72--109)105 (69--118)0.494 Mean arterial blood pressure, mmHg102 (85--110)78 (71--94)\< 0.001 CVP, mmHg9 (7--10)11 (9--14)0.058Cardiovascular phenotypes ACP (%)3 (17)11 (48)0.051 Severe ACP (%)1 (5)8 (35)0.054 LV failure3\*\*\* (17)14 (61)0.009 Hypovolemia2 (11)1 (4)0.573 Hyperkinesia6 (33)7 (30)1.00 Normal hemodynamic profile8 (44)5 (22)0.179Echocardiographic indices Cardiac index\*\*\*\* (L/min/m^2^)3.1 (2.5--4.2)2.5 (2.0--3.0)0.034 RVEDA/LVEDA0.55 (0.37--0.60)0.70 (0.54--0.80)0.021 RVFAC, %46 (35--50)33 (24--39)0.002 TAPSE, mm25 (23--29)18 (16--22)\< 0.001 Tricuspid S′, cm/s16.0 (15.0--20.5)12.2 (11.0--13.4)0.005 TR peak velocity, m/s3.2 (2.9--3.6)2.9 (2.4--3.2)0.113 IVC diameter, mm22 (19--26)22 (21--24)0.762 LVEF (%)52 (44--61)44 (28--59)0.265 LVOT VTI, cm22 (18--25)18 (13--24)0.106 Mitral E/E′ ratio7.3 (6.5--10.9)7.8 (6.1--10.6)0.730Outcome ICU mortality\*\*\*\*\* (%)1 (6)9 (39)0.025Abbreviations: *BMI* body mass index, *SAPSII* Simplified Acute Physiology Score, *SOFA* Sepsis Organ Failure Assessment, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *CPK* creatinine phosphokinase, *RR* respiratory rate, *PEEP* positive end-expiratory pressure, *CVP* central venous pressure, *ACP* acute cor pulmonale, *LV* left ventricle, *RVEDA* right ventricular end-diastolic area, *LVEDA* left ventricular end-diastolic area, *RVFAC* right ventricular fractional area change, *TAPSE* tricuspid annular plane systolic excursion, *TR* tricuspid regurgitation, *IVC* inferior vena cava, *LVEF* left ventricular ejection fraction, *LVOT* left ventricular outflow tract, *VTI* velocity-time integral, *ICU* intensive care unit\*One patient had anterior negative T-wave in the COVID-19 group; 2 patients had inferior negative T-wave, and 1 patient had anterior negative T-wave in the flu group \[[@CR2]\]\*\*Calculated as the tidal volume divided by the driving pressure (difference between the inspiratory plateau pressure and positive end-expiratory pressure)\*\*\*One patient was diagnosed with a Tako-tsubo syndrome during transesophageal echocardiography examination performed shortly after tracheal intubation, after 6 days of high-flow nasal cannula; full recovery of left ventricular systolic function was documented under mechanical ventilation 10 days later\*\*\*\*Measured using the Doppler method applied at the left ventricular outflow tract\*\*\*\*\*As per April 24, with still 6 patients hospitalized in the intensive care unit, 5 of them being invasively ventilatedTable 2Evolution of hemodynamic profile during daily transesophageal echocardiography assessments of COVID-19 patients ventilated for ARDSDay 1 (***n*** = 18)Day 2 (***n*** = 10)Day 3 (***n*** = 12)***p*** valueRespiratory parameters PaO~2~/FiO~2~130 (81--217)128 (100--210)137 (98--187)0.066 PaCO~2~, mmHg44 (33--51)50 (32--56)47 (37--57)0.964 RR, breaths/min24 (22--27)27 (20--28)24 (24--30)0.651 PEEP, cmH~2~O10 (8--12)10 (8--13)10 (10--12)0.444 Plateau pressure, cmH~2~O23 (20--26)22 (18--27)24 (21--27)0.127 Driving pressure, cmH~2~O12 (10--15)11 (9--12)13 (11--17)0.368 Tidal volume, mL/kg5.2 (4.5--6.2)5.3 (4.6--6.6)5.5 (4.3--6.7)0.210 Respiratory-system compliance\*, mL/cmH~2~O38 (31--45)33 (33--53)37 (28--45)0.692Hemodynamic parameters Heart rate, bpm90 (72--109)93 (78--107)98 (89--104)0.368 CVP, mmHg9 (7--10)7 (6--10)9 (5--13)0.678 Mean blood pressure, mmHg102 (85--110)105 (87--110)95 (84--109)0.102 Lactate, mmol/L1.17 (0.89--1.57)1.85 (1.24--3.01)1.62 (1.49--1.95)0.264Echocardiography indices Cardiac index (L/min/m^2^)\*\*3.1 (2.5--4.2)2.8 (2.6--3.9)4.1 (3.2--4.8)0.115 RVEDA/LVEDA0.55 (0.37--0.60)0.53 (0.35--0.66)0.55 (0.48--0.58)0.549 RVFAC, %46 (35--50)40 (33--46)40 (32--58)0.821 TAPSE, mm25 (23--29)24 (20--28)25 (23--28)0.368 Tricuspid S′, cm/s16.0 (15.0--20.5)16.1 (14.0--18.1)16.8 (14.9--19.9)0.867 TR peak velocity, m/s3.2 (2.9--3.6)3.0 (2.7--3.7)3.6 (2.4--3.9)0.060 IVC diameter, mm22 (19--26)24 (14--30)22 (17--24)1.000 LVEF, %52 (44--61)46 (41--64)55 (49--60)0.549Abbreviations: *RR* respiratory rate, *PEEP* positive end-expiratory pressure, *CVP* central venous pressure, *RVEDA* right ventricular end-diastolic area, *LVEDA* left ventricular end-diastolic area, *RVFAC* right ventricular fractional area change, *TAPSE* tricuspid annular plane systolic excursion, *TR* tricuspid regurgitation, *IVC* inferior vena cava, *LVEF* left ventricular ejection fraction\*Calculated as the tidal volume divided by the driving pressure (difference between the inspiratory plateau pressure and positive end-expiratory pressure)\*\*Measured using the Doppler method applied at the left ventricular outflow tract

The higher prevalence of LV failure and lower cardiac index in patients with flu-related ARDS is presumably related to septic cardiomyopathy since they sustained associated septic shock more frequently than COVID-19 patients. Depressed indices of RV systolic function and elevated central venous pressure reflecting systemic venous congestion reflect the higher prevalence of RV failure in flu ARDS patients (Table [1](#Tab1){ref-type="table"}). This presumably results from the lower P/F, higher driving pressure, and lower respiratory-system compliance observed in this group. COVID-19 patients with ACP tended to have lower respiratory-system compliance than their counterparts, presumably due to distinct ARDS phenotypes \[[@CR6]\]. This pilot study is limited by its small sample size and the retrospective comparison with historical flu-related ARDS patients.

This first study assessing hemodynamically ventilated COVID-19 patients with TEE shows a lower prevalence of LV and RV failure than in flu-related ARDS patients. Whether herein reported cardiovascular phenotypes are influenced by the type of COVID-19 ARDS remains to be determined \[[@CR6]\]. These preliminary data warrant confirmation in large-scale multicenter cohorts.
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